PP405 may damage hairfollicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.
A user who experienced hair loss and stopped finasteride 4.5 years ago is considering restarting treatment with finasteride and oral minoxidil, questioning if their hairfollicles are still recoverable. Responses suggest that hairfollicles may not die and can potentially be revived even after many years, with some users sharing personal success stories using treatments like minoxidil, finasteride, microneedling, and RU58841.
Cannabis and THC may have mixed effects on hair, with some studies suggesting potential negative impacts on hair growth in isolated hairfollicles, but these results are hard to apply to living humans. Treatments like minoxidil and finasteride are commonly used for hair loss, and the effects of cannabis might be neutral or vary based on individual factors.
The user noticed hair regrowth after 4 years of hair loss, coinciding with lifestyle improvements like quitting smoking, exercising, and a better diet. They are curious if dormant follicles can recover under improved conditions.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hairfollicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
Hairfollicles often go dormant rather than die, and treatments like minoxidil can help revive them. Scalp health and stimulation, such as massages and using products like sulphur soap, are also important for hair regrowth.
PP405 may revive dormant hairfollicles but is unlikely to help with long-term baldness where follicles are replaced by scar tissue. It is seen as a potential adjunct to treatments like minoxidil and finasteride, but its effectiveness on deeply fibrotic or scarred areas is doubtful.
MCL-1 is important for hairfollicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.
HairClone is developing cell replacement treatments to rejuvenate and generate hairfollicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
The conversation discusses difficulty in distinguishing between new hair growth and thinning hair at the temples after using microneedling and a rosemary peppermint topical for four weeks. The advice given is to wait a few months to see if the hairs grow out to determine their nature.
Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hairfollicles and preventing cell death, offering a localized treatment without systemic side effects.
Tretinoin can cause non-telogen hair loss in some men by inducing catagen-like changes in hairfollicles and through retinoid toxicity, especially when used with minoxidil. Some users report hair loss even when using retinoids on the face, while others experience benefits when combined with treatments like finasteride and minoxidil.
A 23-year-old male is using topical minoxidil and oral finasteride for hair regrowth, noticing some progress on his temples and seeking advice on whether this indicates overall scalp improvement. Users suggest patience, as regrowth can take time, and advise against a hair transplant, noting that the current treatment seems effective.
Hairfollicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.
Hair transplant recipients are concerned about whether dormant follicles are permanently damaged by incisions, but some believe undamaged follicles could still regrow if a treatment like PP405 is effective. Opinions vary on the impact of transplants on original follicles, with some suggesting treatments like finasteride can help regrow hair.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
DHT may inhibit hair growth by affecting mitochondrial function, leading to hairfollicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.
PP405 is not a cure for hair loss but may reactivate dormant hairfollicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.
PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hairfollicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hairfollicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
Diffuse thinners often experience more hair regrowth with DHT blockers like finasteride, possibly due to less DHT sensitivity and the presence of miniaturized, not completely bald, follicles. However, regrowth varies widely among individuals, influenced by factors like genetics, the stage of hair loss, and treatment methods such as minoxidil, microneedling, and dermarolling.
PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hairfollicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.
The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.
User "Jordan_cadagan" shares 11-month progress using minoxidil and finasteride for hair growth, with impressive results. Users discuss application methods, ice baths possibly helping, and daily dosages.
Sugary beverages increase the risk of pattern hair loss in men by 57%, and type 2 diabetes is linked to female pattern hair loss. Reducing sugar intake and using treatments like finasteride and minoxidil may help manage hair loss.
The user stabilized hair loss with oral finasteride, dutasteride, and topical minoxidil, and underwent a stem cell and PRP procedure. Recent increased hair shedding may be due to restarting dermarolling, affecting minoxidil absorption, or the waning effects of the stem cell treatment.
Coffee may negatively impact hair health due to its vasoconstrictor effects, potential to increase DHT, and interference with nutrient absorption. There is no strong clinical evidence linking caffeine to hair loss or regrowth in humans, but moderation is advised.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
The user switched from finasteride to dutasteride for hair loss but faced increased shedding and anxiety, regretting not staying with finasteride longer. Other users shared mixed experiences, advising patience with dutasteride, as it may take up to a year to show results.
The user started using finasteride and topical minoxidil in September 2023, later adding a Theradome laser helmet, which helped reduce hair shedding significantly. The user reports improved hair coverage and stability, attributing most progress to the medications rather than the helmet.